


The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1-20. (Cancelled)

21. (Previously presented) A compound of the general formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;


R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1 , where $\text{X}^1 = \text{H}, \text{Cl}, \text{Br}, \text{I}$ or F ;

R_1 is H, or C_1 to C_7 alkyl, phenyl, or substituted phenyl;


$\text{R}_2, \text{R}_3, \text{R}_4$ and R_5 are H or C_1 to C_7 alkyl, and $\text{R}_1, \text{R}_2, \text{R}_3, \text{R}_4$ and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain.


22. (Previously presented) A compound of formula




23. (Previously presented) A compound of formula




24. (Previously presented) A compound of formula



25. (Previously presented) A compound of formula




26. (Previously presented) A compound of formula



27. (Currently amended) A method of treatment of a condition or disorders related to cannabinoid-regulated systems in a patient in need thereof, wherein if said compound is an agonist of a CB1 receptor then said condition is selected from the group consisting of acute pain; chronic pain; loss of appetite, and nausea and vomiting; and wherein if said compound is a silent antagonist of a CB1 receptor then said condition is obesity;

comprising the step of

administering to said patient a quantity of a compound of formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;


R₁ is H, C₁ to C₇ alkyl, phenyl, or substituted phenyl;

R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and

X is CH₂ or a saturated or unsaturated C₂ carbon chain,

wherein said compound is administered in a quantity sufficient to ameliorate symptoms of said condition or disorder.

28. (Currently amended) A method for treating pain in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and said agonist has the chemical formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;


R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;

R₁ is H, C₁ to C₇ alkyl, phenyl, or substituted phenyl;


R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and

X is CH₂ or a saturated or unsaturated C₂ carbon chain, with the proviso that if R is CH₃, then X must be CH₂ or a saturated C₂ carbon chain.


29. (Previously presented) The method of claim 28 wherein said agonist is selected from the group consisting of



and



30. (Currently amended) A method for treating nausea in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;


R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;

R₁ is H, C₁ to C₇ alkyl, phenyl, or substituted phenyl;


R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and

X is CH₂ or a saturated or unsaturated C₂ carbon chain, with the proviso that if R is CH₃, then X must be CH₂ or a saturated C₂ carbon chain.

31. (Previously presented) The method of claim 13, wherein said agonist is selected from the group consisting of



and



32. (Currently amended) A method for treating obesity in a patient comprising administering to said patient an effective dose of a silent antagonist of a CB1 cannabinoid receptor wherein said agonist silent antagonist includes a sulfonamide moiety, and wherein said agonist silent antagonist has the chemical formula

